Neoadjuvant Tebentafusp in Patients With Metastatic Uveal Melanoma

Uveal melanoma (UM) is a rare type of melanoma, with an incidence of 4.4 cases per million in Europe each year. During recent years, different treatment approaches have been tested in patients with metastatic UM. Responses have been reported primarily with localized treatment in patients with a limited number of liver metastases. In cases of diffuse liver involvement or extrahepatic disease, systemic therapies are justified. However, to date, systemic therapies such as targeted therapy with selumetinib or conventional chemotherapy have failed in metastatic UM. Neo-TB is a Phase II, single arm

Trial Details

NCT ID
NCT07057596
Phase
PHASE2
Sponsor
Grupo Español Multidisciplinar de Melanoma
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • Tebentafusp
Locations (sample)
  • Berlin, State of Berlin, Germany|52.52437,13.41053
  • L'Hospitalet de Llobregat, Barcelona, Spain|41.35967,2.10028
  • Madrid, Madrid, Spain|40.4165,-3.70256
  • Valencia, Valencia, Spain|39.47391,-0.37966

Key Eligibility Criteria

  • Patients must have histologically confirmed metastatic uveal melanoma with Human leukocyte antigen-A\*0201 positive determined by local assay.
  • Patients with histologically proven metastatic uveal melanoma in the liver with reectable or potentially resectable liver metastases evaluated by i…
  • Minor resection (i.e., less than a hemihepatectomy)
  • Major resection (i.e., hemihepatectomy or extended hepatectomy)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →